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Mast cells play a key role in allergic reaction and disorders through the high afﬁnity recep-
tor for IgE (FcεRI) which is primarily activated by IgE and antigen complex. In humans,
mast cells express two types of FcεRI on the cell surface, tetrameric αβγ2 and trimeric
αγ2, whereas in mice, the tetrameric αβγ2 type is exclusively expressed. In human allergic
inﬂammation lesions, mast cells increase in number and preferentially express the αβγ2
type FcεRI. By contrast, in the lesion of non-allergic inﬂammation,mast cellsmainly express
the αγ2 type. Since the β chain ampliﬁes the expression and signaling of FcεRI, mast cell
effector functions and allergic reaction in vivo are enhanced in the presence of the β chain.
In contrast, a truncated β chain-isoform (βT) inhibits FcεRI surface expression. The human
FcεRIβ gene contains seven exons and a repressor element located in the forth intron,
through which FcεRIβ transcription is repressed in the presence of GM-CSF. Regarding the
additional signal regulatory function of the β chain, the β chain ITAM has dual (positive and
negative) functions in the regulation of the mast cell activation. Namely, the FcεRIβ chain
ITAM enhances the mast cell activation signal triggered by a low-intensity (weak) stimula-
tion whereas it suppresses the signal triggered by high-intensity (strong) stimulation. In an
oxazolone-induced mouse CHS model, IgE-mediated mast cell activation is required and
the β chain ITAM is crucially involved. Adenosine receptor, one of the GPCRs, triggers a
synergistic degranulation response with FcεRI in mast cells, for which the β chain ITAM crit-
ically plays positive role, possibly reﬂecting the in vivo allergic response. These regulatory
functions of the FcεRIβ ITAM ﬁnely tune FcεRI-induced mast cell activation depending on
the stimulation strength, enabling the FcεRIβ chain to become a potential molecular target
for the development of new strategies for therapeutic interventions for allergies.
Keywords: mast cell, FcεRI, FcεRIβ chain, ITAM, signal transduction, allergy
INTRODUCTION
Mast cells reside in virtually all organs, among which they are
distributed in a great number particularly in tissues at the inter-
face between inside and outside environments, such as the skin
and mucosal membrane of the airway and intestine, where they
are in close contact with the outside environment and play a key
role in allergic reaction and disorders. In IgE-mediated allergic
reaction mast cells are activated by the aggregation of the IgE-
bound high afﬁnity receptor for IgE (FcεRI) with multivalent
antigen.
The FcεRI consists of three subunits, an α chain, a β chain, and
a disulﬁde-linked dimeric γ chain. The α chain binds IgE with
a high afﬁnity, while the β and γ chains transduce extracellular
signals into the cell through an immunoreceptor tyrosine-based
activation motif (ITAM). The γ chain is essential for FcεRI cell
surface expression while the β chain is dispensable in humans. J.
Hopkin, W. Cockson, and T. Shirakawa originally demonstrated
the β chain gene as an“atopy responsible gene”based on the results
of a genetic association study (Sandford et al., 1993; Shirakawa
et al., 1994). However, functional evidence of the β chain gene as
an“atopy gene”has not yet beendemonstrated. The humanFcεRIβ
gene contains seven exons and two spliced products were recently
found to produce two truncated proteins, βT and MS4A2truc
(Donnadieu et al., 2003; Fiebiger et al., 2005; Cruse et al., 2010). A
repressor element was found in the fourth intron and a molecular
mechanism for the regulation of FcεRIβ gene expression has been
discussed (Takahashi et al., 2006).
The expression of the β chain in specimens from patients with
atopic diseasewas recently investigated and the ratio of αβγ2 FcεRI
toαγ2FcεRIwas compared to that in specimens frompatientswith
non-atopic disease (Matsuda et al., 2009).
The consensus sequence of ITAM contains two canonical tyro-
sine residues (YxxL-x7-YxxL), but the β chain has another non-
canonical tyrosine residue (Y225) between the two canonical
residues (Y219EELHVY225SPIY229SEL). Using β chain knockout
(KO) mice (Dombrowicz et al., 1998; Hiraoka et al., 1999), the
function of the non-canonical tyrosine residue (Y225) of the β
chain ITAM was investigated (Furumoto et al., 2004). The β chain
ITAMwas recently shown towork in tandemwith the stimulation-
intensity (strength), such as the antigen concentration (Nunomura
et al., 2005; Xiao et al., 2005). Adenosine with IgE antigen stimu-
lation at a low concentration has also been suggested to enhance
mast cell activation remarkably, and this synergistic activationmay
also be dependent on the β chain ITAM (Nunomura et al., 2010).
We think that this type of β chain-induced enhancement
may play a crucial role in allergic reactions occurring in vivo,
such as in bronchial asthma. The IgE-FcεRI-mast cell system was
shown to be critically involved in an oxazolone-induced contact
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hypersensitivity (CHS) mouse model (Kobayashi et al., 2010). The
role of the β ITAM has also been examined using this mouse
model.
In this review we have mainly focused on recent ﬁndings
regarding the roles of the FcεRIβ chain, especially the dual (pos-
itive and negative) regulatory roles of the FcεRIβ chain ITAM,
both in vitro and in vivo. Detailed reviews on FcεRI signaling,
including this topic, are available (Kraft et al., 2004; Rivera and
Gilﬁllan, 2006; Kraft and Kinet, 2007; Rivera et al., 2008). Findings
regarding the novel roles of the FcεRIβ chain in the ﬁne-tuning
of mast cell activation will contribute to investigation in new
areas for the development of therapeutic interventions for allergic
diseases.
STRUCTURE OF THE FCεRIβ-CHAIN
The cDNA for the FcεRIβ chainwas identiﬁed froma cDNA library
derived from a rat mucosal mast cell tumor in 1988 (Kinet et al.,
1988). Subsequent studies identiﬁed mouse and human FcεRIβ
chain counterparts (Blank et al., 1989; Ra et al., 1989; Küster
et al., 1992). The human and mouse FcεRIβ chain genes contain
seven exons. The start and stop codons are located in exon 1 and
exon 7, respectively (Figure 1A). The homology among the amino
acid sequences of the rat, mouse, and human β chain proteins is
approximately 69% (Küster et al., 1992).
Recent studies have demonstrated that the human FcεRIβ chain
gene encodes two additional spliced products (Donnadieu et al.,
2003; Fiebiger et al., 2005; Cruse et al., 2010). These splicing vari-
ants produce two truncated proteins, which are designated βT and
MS4A2truc (Figures 1B,C). βT retains the ﬁfth intron, which con-
tains a stop codon. Unlike βT, MS4A2truc, a novel β isoform, does
not retain this intron sequence and lacks exon 3. Whether the
murine FcεRIβ chain gene also encodes βT and/or MS4A2truc is
currently unclear.
In humans and mice, the FcεRIβ chain is a component
of the tetrameric FcεRI complex, which is expressed in mast
cells and basophils. The tetrameric form (αβγ2) of FcεRI is
composed of an α chain, a β chain, and a homodimer of γ
chains. The full-length FcεRIβ chain protein spans the plasma
membrane four times in a manner such that both its N-
and C-terminal regions protrude toward the cytoplasm. The
A
B
C
FIGURE 1 | FcεRIβ gene encoding the full-length form of the
protein (β) and two truncated alternative splicing products (βT and
MS4A2truc). (A) FcεRIβ gene structure. (B)Transcript structure. (C)
FcεRIβ protein structure. βT and MS4A2truc lack the C-terminal
cytoplasmic region and transmembrane (TM) region (dashed line),
respectively.
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C-terminal cytoplasmic region of the FcεRIβ chain possesses
an ITAM, which is immediately phosphorylated upon FcεRI
crosslinking.
REGULATION OF THE HUMAN FCεRIβ GENE EXPRESSION
A sequence located in the fourth intron has been shown to serve as
a repressor element by screening for cis-acting elements over the
entire region of the human FcεRIβ gene (Takahashi et al., 2003).
This element binds the transcription factor MZF-1. The MZF-
1 antisense inhibits the suppressive effect of the element on the
FcεRIβ promoter and increases the quantity of FcεRIβ mRNA,
indicating that MZF-1 represses human FcεRIβ gene expression
via the element in the fourth intron. This transcriptional repres-
sion byMZF-1 requires FHL3 as a cofactor (Takahashi et al., 2005).
Furthermore, MZF-1 and FHL3 form a complex with a high mol-
ecular mass by binding additional proteins in the nucleus. We
identiﬁed NFY, which reportedly binds HDACs, as a constituent
of the repressor complex in the fourth intron (Takahashi et al.,
2006).
GM-CSF,which reportedly decreases FcεRI expression, induces
the accumulation of FHL3 in the nucleus, in accordance with
the repressive role of FHL3 in FcεRIβ expression. In the pres-
ence of GM-CSF, the C-subunit of NFY forms a ternary com-
plex with MZF-1/FHL3 and recruits HDAC1 and HDAC2 on
the fourth intron of FcεRIβ gene in human mast cells. As a
result, HDACs repress FcεRIβ transcription by deacetylating his-
tones (Figure 2). These mechanisms are involved not only in the
cell type-speciﬁc repression of FcεRIβ expression in differenti-
ating hematopoietic cells but also in the repression of FcεRIβ
expression in peripheral cells, such as mast cells, under speciﬁc
circumstances.
PREFERENTIAL EXPRESSION OF FCεRIβ CHAIN AND ITS
ROLES OBSERVED IN THE MAST CELLS OF GIANT PAPILLAE
Although the existence of both FcεRIαβγ2 and αγ2 receptor
subtypes was theoretically anticipated, the distribution of the
FcεRIαβγ2 and αγ2 isoforms in human mast cells in vivo has not
been determined. The precise pathophysiological roles of FcεRIβ
in human atopic diseases remain unknown.
Atopic keratoconjunctivitis (AKC; Foster and Calonge, 1990;
Tuft et al., 1991) and vernal keratoconjunctivitis (VKC) (Bonini
et al., 2000) are the most severe form of chronic allergic con-
junctivitis, showing the massive inﬁltration of mast cells and
signiﬁcantly high serum and tear IgE levels compared with those
in normal controls (Tuft et al., 1991). VKC and AKC tend to
form giant papillae at the upper tasal conjunctiva (Abu el-Asrar
et al., 1989; Tuft et al., 1991; Bonini et al., 2000). Histopatho-
logical analyses using an anti-FcεRIβ speciﬁc antibody (Matsuda
et al., 2008) and performed by our group revealed that the den-
sities of FcεRIβ+ cells, FcεRIα+ cells, tryptase+ cells, and the
ratio of FcεRIβ+/tryptase+ cells were signiﬁcantly increased in
giant papillae compared with conjunctiva from non-allergic con-
junctivitis patients with conjunctivochalasis and superior limbic
keratoconjunctivitis (Matsuda et al., 2009; Figure 3). The ratio of
the FcεRIβ+ mast cell number/FcεRIα+ mast cell number in the
giant papillae was also signiﬁcantly higher than that in the non-
allergic conjunctivitis patients. FcεRIβ+ cells were preferentially
localized within and around the epithelial tissue, suggesting that
the FcεRIβ+ mast cells around the epithelium in the mucosa of
allergic patients are easily able to access allergens.
Because the shRNA-mediated diminution of the FcεRIβ chain
in human mast cells signiﬁcantly downregulated cell surface
FcεRI expression,and IgE-dependentmediator release/production
FIGURE 2 | GM-CSF-induced repression of FcεRIβ gene expression in human mast cells. HDACs, which were recruited to the human FcεRIβ gene through
the element in the fourth intron by MZF-1/FHL3/NFY, repressed FcεRIβ transcription through the deacetylation of histones in the presence of GM-CSF.
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FIGURE 3 | Preferential FcεRIβ expression in the mast cells of giant
papillae from patients with atopic keratoconjunctivitis. Anti-FcεRIβ
antibody immunostaining of giant papillae. Immunohistochemical
staining was carried out with giant papillae specimens obtained from
patients with AKC or VKC (A–C) and from patients with superior limbic
keratoconjunctivitis (D,E) using the anti-FcεRIβ antibody (green) and
the anti-FcεRIα antibody (red) or anti-tryptase antibody (red). FcεRIβ
was merged with FcεRIα (C,E). The arrows indicate FcεRIα/β
double-positive cells (yellow) and the arrowheads indicate FcεRIα
single-positive (red) cells. The ﬁgures were reproduced from “Invest
Ophth Vis Sci 50(6):2871–2877, 2009” with written permission from
ARVO.
(unpublished data), FcεRIαβγ2 mast cells are thought to con-
tribute to the pathophysiology of AKC/VKC.
BIOLOGICAL FUNCTIONS OF THE FCεRIβ CHAIN RELATED TO
FCεRI EXPRESSION AND STABILITY
The requirement of the FcεRIβ chain for FcεRI cell surface expres-
sion differs between rodents and humans. While the FcεRIβ chain
is required for surface expressionof the receptor in rodents,human
FcεRI can be expressed on the cell surface in the absence of
the FcεRIβ chain. Therefore, human trimeric FcεRI (αγ2) can
be expressed in β chain-deﬁcient cell types, such as monocytes,
Langerhans cells, and dendritic cells.
However, the FcεRIβ chain can enhance FcεRI cell surface
expression in humans by promoting the maturation (glycosy-
lation) of the FcεRIα chain protein (Donnadieu et al., 2000b).
Donnadieu et al. showed that immature FcεRIα chain protein
accumulates in the ER in the absence of the FcεRIβ chain protein.
Moreover, the FcεRIβ chain increases the stability of surface FcεRI
complexes (Donnadieu et al., 2000b). Trimeric FcεRI complexes
are unstable when exposed to a strong detergent (Triton-X100),
whereas tetrameric FcεRI complexes remain stable when exposed
to the same detergent.
The presence of a full-length FcεRIβ chain is thus widely
believed to result in a fourfold to sixfold enhancement of FcεRI
surface expression. The truncated form of βT lacks the C-terminal
cytoplasmic region, including the ITAM. Interestingly, the βT pro-
tein is unable to support the maturation of the nascent FcεRIα
chain. Therefore, FcεRI surface expression was found to be unal-
tered following introduction of βT cDNA into CHO cells express-
ing trimeric FcεRI (αγ2) (Fiebiger et al., 2005). However, the
participation of the FcεRIβ chain ITAM domain in the matura-
tion of the FcεRIα chain remains unclear. Further investigation is
required to elucidate the role of the FcεRIβ chain ITAM in this
maturation process.
BASAL FUNCTIONS OF THE FCεRIβ CHAIN IN FCεRI
SIGNALING
Upon the engagement of FcεRI with IgE and a multivalent anti-
gen, the rapid tyrosyl phosphorylation of the FcεRIβ and γ chain
ITAMs is initiated; this, in turn, leads to effector functions, such
as degranulation, the de novo synthesis of lipid mediators, and
cytokine production. The tyrosine phosphorylation of the FcεRIβ
chain ITAM occurs through trans-phosphorylation by the src
family tyrosine kinase (PTK) Lyn.
Earlier studies found that the FcεRIβ chain acts as an ampli-
ﬁer of FcεRIγ-mediated signaling. The mutation of two canonical
tyrosines in the FcεRIβ chain ITAM has been shown to abolish
the phosphorylation of both the FcεRIβ and γ chain ITAMs in a
rodent mast cell line (Jouvin et al., 1994). Similarly, Lyn KO mast
cells showed a reduction in the phosphorylation of the FcεRIβ
and γ chains (Nishizumi and Yamamoto, 1997). Furthermore,
in ﬁbroblasts expressing human FcεRI, it was revealed that upon
receptor engagement, cells expressing the trimeric form of FcεRI
(αγ2) exhibit less Lyn-dependent tyrosine phosphorylation of the
FcεRIγ chain ITAM and less subsequent tyrosine phosphorylation
of Syk kinase (Lin et al., 1996) compared to cells expressing the
tetrameric form of FcεRI (αβγ2).
These studies show that the FcεRIβ chain is associated with
a ﬁvefold- to sevenfold increase in FcεRI signaling through the
FcεRIγ chain ITAM. Researchers have long recognized the clas-
sical function of the FcεRIβ chain ITAM as a signal ampliﬁer.
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However, studies by our group recently revealed novel functions
of the FcεRIβ chain ITAM and Lyn in the negative regulation of
cell activation and effector functions.
INSIGHTS INTO THE NOVEL ROLES OF THE FCεRIβ CHAIN IN
FCεRI SIGNALING AND MAST CELL ACTIVATION
The generation of FcεRIβ chain KO mice (Hiraoka et al., 1999)
and the development of retroviral gene transfer have contributed
greatly to the establishment of FcεRI reconstitution systems in
murine mast cells. This system allows us to investigate the biolog-
ical functions of the FcεRIβ chain in mast cells. Polymorphisms
(I181L, V183L, and E237G) in the coding region of the FcεRIβ
chain have been found to be associated with allergic disorders.
However, reconstitution studies did not ﬁnd any effects of these
variants on mast cell effector functions (Donnadieu et al., 2000a;
Furumoto et al., 2000).
Interestingly, the ITAM sequence of the FcεRIβ chain is
unique, differing from the consensus ITAM sequence. While
the FcεRIγ chain ITAM (YTGLNTRSQETYETL) contains the
consensus sequence (YxxL-x7-YxxL), the FcεRIβ chain ITAM
(Y219EELHVY225SPIY229SEL) contains a third non-canonical
tyrosine (Y225) between two canonical tyrosine residues (Y219
and Y229; Figure 4). A mutational analysis of these tyrosine
residues in the ITAM(tyrosine replacedwith phenylalanine,Y→F)
performed by our group revealed novel functions of the FcεRIβ
chain (Furumoto et al., 2004).
The N-terminal canonical tyrosine (Y219) in the FcεRIβ chain
ITAM is essential for the modulation of the effects of the FcεRIβ
chain because of its ability to associate with Lyn upon FcεRI
engagement, whereas the other canonical tyrosine (Y229) is dis-
pensable for the interaction of the FcεRIβ chain with Lyn. Mast
cells (αβFYFγ2) harboring mutations in Y219 and Y229 showed
a reduction in degranulation and cytokine production when
stimulated with antigen at sufﬁcient concentration, triggering an
optimal degranulation response. Under the same stimulation con-
ditions, the additional introduction of mutation of the middle
non-canonical tyrosine (Y225) in αβFYFγ2 mast cells (αβFFFγ2)
unexpectedly resulted in a marked increase in cytokine produc-
tion (IL-6 and IL-13) with no affect on degranulation. This ﬁnding
was associated with a reduction in the tyrosine phosphorylation of
SHIP-1, a negative regulator of signaling. Y225 plays a crucial role
in the interaction between the FcεRIβ chain and SHIP-1 follow-
ing FcεRI stimulation. Thus, the FcεRIβ chain ITAM may mediate
negative signals affecting mast cell responses.
Further studies have demonstrated that the strength of FcεRI
engagement determines whether the FcεRIβ chain functions as a
positive or negative regulator (Figure 5). Upon exposure to low-
intensity stimuli, the Lyn-dependent amplifying signals through
FcεRIβ can mediate weak positive signals but are insufﬁcient
to induce negative signals including SHIP-1; meanwhile, upon
exposure to high-intensity stimuli, the FcεRIβ chain increases
Lyn-dependent signals considerably, robustly activating both the
positive and negative signals simultaneously. Consequently, the
FcεRIβ chain increases degranulation and cytokine production in
the presence of low-intensity stimuli, whereas it decreases degran-
ulation and cytokine production in the presence of high-intensity
stimuli (Nunomura et al., 2005; Xiao et al., 2005).
Hck and phospholipase C β3 (PLCβ3) are reportedly involved
in regulation of mast cell functions by the FcεRIβ chain and Lyn
(Hong et al., 2007; Xiao et al., 2011). Hck is a PTK expressed at
levels of 30-fold to 50-fold less than Lyn in mast cells. However,
Hck KO mast cells exhibit a sustained increase in Lyn activity fol-
lowing “high-intensity” FcεRI stimulation. In this context, Hck
counteracts the negative roles of Lyn and thereby acts as a positive
regulator of mast cell activation. Consequently, degranulation and
cytokine production in Hck KO mast cells are decreased.
Similar to Hck KO mast cells, PLCβ3 KO mast cells also show
increased Lyn activity. However, although PLCβ3 KO mast cells
also exhibit reduced cytokine production, degranulation is normal
in these cells. A constitutive interaction among PLCβ3 and the
FcεRIβ chain, Lyn, and the SHP-1 protein phosphatase has been
observed. In this context, PLCβ3 and SHP-1 regulate mast cell
cytokine production by suppressing Lyn and SHIP-1 activity.
Importantly, the FcεRIβ chain can provide a docking site for the
formation of a negative signalosome that includes Lyn, SHP-1, and
SHIP-1.
With regard to the roles of Lyn in FcεRI-dependent mast cell
degranulation response, however, contradicting conclusions have
been reported.Nishizumi et al. and J. Rivera’s group independently
demonstrated that Lyn KO mast cells (129/sv or 129/sv×C57BL/6
[less than N8]) exhibit enhanced degranulation response follow-
ing high-intensity FcεRI engagement (Nishizumi and Yamamoto,
1997; Odom et al., 2004). However, more recent studies have
reported that Lyn KO mast cells (C57BL/6 or 129/sv ×C57BL/6
[N8]) are poorly degranulated upon high-intensity FcεRI engage-
ment. Together, these ﬁndings raise the possibility that the genetic
backgroundof thesemicemay affect the positive andnegative roles
of Lyn on the degranulation response. In contrast, the enhanced
cytokine responses of Lyn KO mast cells are independent of the
genetic background of the mice.
The simultaneous stimulation of FcεRI and adenosine recep-
tors in mast cells triggers a synergistic degranulation response,
FIGURE 4 | FcεRIβ chain ITAM sequence. The FcεRIβ chain contains a non-canonical tyrosine residue at position 225, which is involved in the negative
regulation for mast cell activation.
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FIGURE 5 | Positive and negative regulation of FcεRI-dependent mast
cell activation by the FcεRIβ ITAM.Y→F β (αβFFFγ2) mast cells exhibit
reduced degranulation and cytokine production following exposure to a
“low-intensity” stimulus (left dashed line), whereas the cells exhibit
increased degranulation and cytokine production following exposure to a
“high-intensity” stimulus (right dashed line). The FcεRI stimulation that
induces the optimal degranulation response of wild-type (αβYYYγ2) mast
cells (middle dashed line) triggered a normal degranulation response but
increased cytokine production in αβFFFγ2 mast cells.
even when the FcεRI stimulation is of “lower intensity” than
the threshold strength (Laffargue et al., 2002). Additionally, an
early-phase allergic reaction in asthmatic subjects but not in
non-asthmatic subjects is induced by the inhalation of a low-
dose mite allergen (Bryant and Burns, 1976; Dohi et al., 1990;
M’Raihi et al., 1990). These ﬁndings suggest that the augmenta-
tion of “low-intensity”FcεRI stimulus-mediated degranulation by
an exacerbating factor, such as adenosine, may be responsible for
the high susceptibility of asthmatic patients to low-dose allergens.
We recently reported a positive role for the FcεRIβ chain ITAM
in the regulation of the synergistic degranulation response fol-
lowing “low-intensity” FcεRI stimulation and adenosine receptor
stimulation, possibly reﬂecting in vivo allergic reactions (Nuno-
mura et al., 2010). In this report, we demonstrated that adenosine
fails to increase the degranulation response in αβFFFγ2 mast cells.
Conversely, the degranulation response of αβYYYγ2, αβYFYγ2, and
αβFYFγ2 mast cellswas enhanced, suggesting that the two canonical
tyrosine residuesY219 andY229) in the FcεRIβ ITAMare sufﬁcient
for the ampliﬁcation of the degranulation response by adeno-
sine. This phenomenon was found to be associated with increased
phosphorylation of Thr308 in Akt, reﬂecting PI3K activity.
However, the question of how the FcεRIβ chain ITAM regu-
lates the ampliﬁcation of the degranulation response and PI3K
signaling remains. Of particular note, the tyrosine phosphory-
lation of the FcεRIβ chain was synergistically increased upon
costimulation with FcεRI and adenosine receptors, representing
one mechanism that mediates the synergy between the two signal-
ing cascades. However, how adenosine receptor signaling enhances
the FcεRI-mediated tyrosine phosphorylation of the FcεRIβ chain
remains unclear. Further studies are needed to assess the potential
role of adenosine receptors in this process.
FCεRIβ CHAIN AMPLIFIES IGE-MEDIATED MAST CELL
EFFECTOR FUNCTIONS IN VIVO
Mouse mutants for c-Kit that genetically lack mast cell popu-
lations can undergo engraftment with wild-type or genetically
altered mast cells (Tsai et al., 2005; Metz et al., 2007). WBB6F1-
W/Wv and KitW-sh/W-sh mice are two representative examples of
mast cell-deﬁcient mouse strains. Using the adoptive transfer of
mast cells into these mast cell-deﬁcient mice, several groups have
investigated the role of mast cells in hapten-induced CHS. For
instance, mast cells are required for the optimal elicitation of the
cutaneous inﬂammation response associated with mouse models
of oxazolone-induced CHS (Bryce et al., 2004; Nakae et al., 2005,
2006; Kakurai et al., 2006). Although the requirement of mast cells
for the elicitationof CHSdifferswith the type and concentrationof
haptens, the CHSmodel employing oxazolone is suitable for inves-
tigating the in vivo effector functions of mast cells. A recent study
by our group revealed that the abrogation of IgE-mediated mast
cell activation in the effector phase prevents oxazolone-mediated
CHS without affecting the immune response in the sensitization
phase (Kobayashi et al., 2010).
Furthermore, using the adoptive transfer of αβYYYγ2 and
αβFFFγ2 mast cells into WBB6F1-W/Wv mice, we investigated
whether the FcεRIβ chain ITAM regulates the CHS response to
oxazolone in mice. In the study, an amplifying role was demon-
strated for the FcεRIβ chain ITAM in IgE-mediated in vivo mast
cell effector functions, suggesting that the in vivo activation of
mast cells may occur through “low-intensity FcεRI stimulation.”
CONCLUDING REMARKS
The major focus of this review was the novel roles of the FcεRIβ
chain both in vitro and in vivo, especially the dual function of
the β chain ITAM. In the β chain ITAM, an additional non-
canonical tyrosine residue (Y225) is present between the two
canonical residues (Y219, Y229). The β chain positively and neg-
atively regulates FcεRI signaling in response to low-intensity and
high-intensity (weak and strong) stimuli, respectively. Lyn kinase
associates with the β chain ITAM (Y219) and has a dual-function
in the regulation of FcεRI signaling (Furumoto et al., 2004). Hck
andPLCβ3 suppress thenegative roles of Lyn inmast cell activation
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(Hong et al., 2007; Xiao et al., 2011). Interactions among PLCβ3
and theβ chain,Lyn,andSHP-1have been reported; in this context,
PLCβ3 and SHP-1 regulate mast cell cytokine production by sup-
pressing Lyn and SHIP-1 activity. In this compartment, the β chain
mayprovide adockingplatform for the formationof anegative sig-
nalosome that includes Lyn, SHP-1 and SHIP-1. Importantly the
non-canonical tyrosine residue in the β chain ITAM (Y225) plays
a crucial role in interaction between the β chain and SHIP-1 fol-
lowing FcεRI stimulation and in the negative regulation of FcεRI
signaling (Furumoto et al., 2004). Regarding the molecular mech-
anisms for the bidirectional (positive and negative) regulation of
theβ chain in FcεRI-inducedmast cell activation,unknownplayers
and compartments requiring further investigation may exist. The
elucidation of the underlying mechanisms responsible for bidi-
rectional response to the strength of the stimuli, such as the type
and concentration of antigen, is particularly important. Deeper
insights into the activation mechanisms for mast cells are needed
for the development of mast cells biology and the pathophysiology
of allergy.
In allergic inﬂammation lesions, such as giant papillae in
AKC and atopic dermatitis, mast cells preferentially express the
tetrameric αβγ2 type FcεRI (Matsuda et al., 2009), indicating that
these mast cells are much more sensitive to antigen stimulation.
In contrast, mast cells mainly express the trimeric αγ2 type FcεRI
in specimens from non-allergic patients. A repressor element was
found in the fourth intron of the FcεRIβ gene and a molecular
mechanism to repress the FcεRIβ gene through this element has
been elucidated (Takahashi et al., 2006). Further investigation of
the regulation of FcεRIβ expression at both the translational and
post translational levels, is required, especially for elucidating the
mechanisms by which the β chain associates with cell surface-
expressed FcεRI. When shRNA for the β chain or phosphorylated
ITAM peptide of the β chain was introduced into human mast
cells, Ag·IgE-induced histamine, PGD2, and cytokine release were
almost completely abolished (unpublished data).
Recent ﬁndings regarding the roles of the FcεRIβ chain in
ﬁne-tuning of FcεRI signaling indicate that the β chain may be
a novel molecular target for the development of new strategies for
therapeutic interventions for allergies.
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